PTC Therapeutics, Inc. Forecast, price target & analysts
PTC Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation
PTC Therapeutics, Inc. Classifications & Recommendation:
PTC Therapeutics, Inc. Price Target
| Target Price | $61.13 |
| Price | $47.20 |
| Potential |
29.52%
register free of charge
|
| Number of Estimates | 15 |
|
15 Analysts have issued a price target PTC Therapeutics, Inc. 2026 .
The average PTC Therapeutics, Inc. target price is $61.13.
This is
29.52%
register free of charge
$112.00
137.29%
register free of charge
$40.00
15.25%
register free of charge
|
|
| A rating was issued by 16 analysts: 10 Analysts recommend PTC Therapeutics, Inc. to buy, 5 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the PTC Therapeutics, Inc. stock has an average upside potential 2026 of
29.52%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion $ | 0.81 | 1.76 |
| 13.97% | 117.95% | |
| EBITDA Margin | -10.11% | 50.39% |
| 10,290.58% | 671.94% | |
| Net Margin | -46.45% | 34.84% |
| 34.31% | 175.00% |
13 Analysts have issued a sales forecast PTC Therapeutics, Inc. 2025 . The average PTC Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an PTC Therapeutics, Inc. EBITDA forecast 2025. The average PTC Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
13 PTC Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average PTC Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -4.73 | 7.73 |
| 43.49% | 263.42% | |
| P/E | 6.11 | |
| EV/Sales | 1.20 |
13 Analysts have issued a PTC Therapeutics, Inc. forecast for earnings per share. The average PTC Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
PTC Therapeutics, Inc....
Current PTC Therapeutics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| B of A Securities |
Locked
➜
Locked
|
Locked | May 09 2025 |
| Barclays |
Locked
➜
Locked
|
Locked | May 08 2025 |
| JP Morgan |
Locked
➜
Locked
|
Locked | May 07 2025 |
| Citigroup |
Locked
➜
Locked
|
Locked | May 07 2025 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | May 07 2025 |
| RBC Capital |
Locked
➜
Locked
|
Locked | May 07 2025 |
| Baird |
Locked
➜
Locked
|
Locked | May 07 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
B of A Securities:
Locked
➜
Locked
|
May 09 2025 |
|
Locked
Barclays:
Locked
➜
Locked
|
May 08 2025 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
May 07 2025 |
|
Locked
Citigroup:
Locked
➜
Locked
|
May 07 2025 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
May 07 2025 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
May 07 2025 |
|
Locked
Baird:
Locked
➜
Locked
|
May 07 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
